Conjugate Or Complex Includes Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/197.11)
-
Publication number: 20130243801Abstract: The present invention relates to a method of treating a subject for an infectious disease. This method involves selecting a subject infected with an infectious disease-causing agent. The infectious disease-causing agent elicits, in the selected subject, an immune response that is insufficient to cure the selected subject of the infectious disease. The method also involves administering to the selected subject a synthetic peptide representing an antigen epitope associated with an immune response to the infectious agent. The immune response to the synthetic peptide is sufficient to treat the selected subject for the infectious disease.Type: ApplicationFiled: August 18, 2011Publication date: September 19, 2013Applicant: NEW YORK UNIVERSITYInventors: Joel D. Ernst, Tyler D. Bold
-
Patent number: 8536153Abstract: The efficient synthesis of phosphatidylinositol mono- to hexa-mannoside (PIM1 to PIM6) is reported. The invention relates to these phosphatidylinositol mono- to hexa-mannosides carrying a linker and a reactive functional group, e.g. the sulfhydryl group, a protein, a fluorescent probe, or a solid phase. The invention further relates to vaccines comprising the PIMs linked to a carrier protein or an antigen.Type: GrantFiled: November 3, 2009Date of Patent: September 17, 2013Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Siwarutt Boonyarattanakalin, Bernd Lepenies
-
Patent number: 8529908Abstract: Conjugated meningococcal capsular saccharides will be introduced into immunization schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. In the invention, tetanus toxoid is used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunizing a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a tetanus toxoid carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunized with a tetanus toxoid.Type: GrantFiled: January 13, 2006Date of Patent: September 10, 2013Assignee: Novartis AGInventor: Cameron John Marshall
-
Publication number: 20130224241Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Inventor: SANOFI PASTEUR INC.
-
Patent number: 8518416Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: GrantFiled: October 24, 2011Date of Patent: August 27, 2013Assignee: Immunology Laboratories, Inc.Inventors: Jiri Pillich, John C. Balcarek
-
Publication number: 20130216571Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.Type: ApplicationFiled: March 15, 2013Publication date: August 22, 2013Inventor: Sanofi Pasteur Inc.
-
Patent number: 8513392Abstract: Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive animation of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.Type: GrantFiled: February 1, 2006Date of Patent: August 20, 2013Assignee: Novartis Vaccines and Diagnostics SRLInventor: Francesco Berti
-
Publication number: 20130202636Abstract: A composition for topical application of a botulinum toxin (including botulinum toxin derivatives) comprises a botulinum toxin and a carrier comprising a polymeric backbone comprising a long-chain polypeptide or nonpeptidyl polymer having attached positively charged branching or “efficiency” groups. The invention also relates to methods for reducing muscle paralysis and other conditions that may be treated with a botulinum toxin, particularly paralysis of subcutaneous, and most particularly, facial, muscles, by topically applying an effective amount of the botulinum toxin and carrier, in conjunction, to the subject's skin or epithelium. Kits for administration are also described.Type: ApplicationFiled: March 18, 2013Publication date: August 8, 2013Applicant: Revance Therapeutics, Inc.Inventor: Revance Therapeutics, Inc.
-
Publication number: 20130195907Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: June 10, 2011Publication date: August 1, 2013Applicant: Norvartis AGInventors: Renata Maria Grifantini, Erika Bartolini, Oretta Finco, Guido Grandi
-
Publication number: 20130189300Abstract: The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a spr0096 antigen and a spr2021 antigen. spr0096 and spr2021 are Streptococcus pneumoniae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.Type: ApplicationFiled: November 7, 2012Publication date: July 25, 2013Applicant: NOVARTIS AGInventor: Novartis AG
-
Publication number: 20130183355Abstract: Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described.Type: ApplicationFiled: June 7, 2011Publication date: July 18, 2013Applicant: NOVARTIS AGInventors: Siddhartha Jain, Derek O'Hagan, Manmohan Singh
-
Publication number: 20130177588Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.Type: ApplicationFiled: January 10, 2013Publication date: July 11, 2013Applicant: SANOFI PASTEUR INC.Inventor: SANOFI PASTEUR INC.
-
Patent number: 8481053Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.Type: GrantFiled: August 30, 2011Date of Patent: July 9, 2013Assignee: Immunology Laboratories, Inc.Inventors: Jiri Pillich, John C. Balcarek
-
Publication number: 20130171188Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.Type: ApplicationFiled: February 27, 2013Publication date: July 4, 2013Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon BIEMANS, Dominique BOUTRIAU, Carine CAPIAU, Philippe DENOEL, Pierre DUVIVIER, Jan POOLMAN
-
Publication number: 20130171187Abstract: Anti-glucan antibodies have been found to be protective against systemic fungal infection with C. albicans, but the protective efficacy can be inhibited by blocking antibodies. The invention provides an immunogenic composition comprising a glucan and a pharmaceutically acceptable carrier, characterised in that, when administered to a mammalian recipient, the composition elicits protective anti-glucan antibodies but does not elicit antibodies which inhibit the protective efficacy of the anti-glucan antibodies. The glucan may be presented on the surface of a protease-treated microbial cell or may be presented as a protein-glucan conjugate. The glucan may be substituted by a glucan mimotope, a peptidomimetic of a glucan mimotope, or nucleic acid encoding a mimotope. Anti-glucan-antibodies show broad spectrum microbicidal activity. ?-glucans are preferred, particularly those containing one or more ?-1,6 linkages.Type: ApplicationFiled: February 26, 2013Publication date: July 4, 2013Inventors: Antonio Cassone, Luciano Polonelli
-
Publication number: 20130164325Abstract: The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.Type: ApplicationFiled: July 6, 2011Publication date: June 27, 2013Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Steven A. Porcelli, Manjunatha M. Venkataswamy
-
Publication number: 20130142822Abstract: Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM197 (a non-toxic variant of diphtheria toxin) and tetanus toxoid, as carrier proteins.Type: ApplicationFiled: October 26, 2012Publication date: June 6, 2013Applicant: NOVARTIS AGInventor: Novartis AG
-
Publication number: 20130129776Abstract: The present invention is drawn to multivalent Salmonella enterica serovar conjugate vaccines comprising conjugates of S. Typhimurium, S. Enteritidis, S. Choleraesuis, S. Typhi, S. Paratyphi A and optionally S. Paratyphi B, wherein the conjugates comprise a hapten antigen and a carrier antigen, wherein at least one of the hapten antigens or carrier antigens is characteristic of the Salmonella enterica serovar. The present invention also provides Salmonella enterica serovar reagent strains to produce the multivalent conjugate vaccines and attenuated Salmonella enterica serovars for use as vaccines.Type: ApplicationFiled: November 6, 2012Publication date: May 23, 2013Applicant: University of Maryland, BaltimoreInventor: University of Maryland, Baltimore
-
Publication number: 20130129777Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.Type: ApplicationFiled: January 25, 2013Publication date: May 23, 2013Applicant: The United States of America as represented by the Secretary, Department of Health and Human ServiceInventor: The United States of America as represented by the Secretary, Department of Health and Human Services
-
Publication number: 20130122037Abstract: Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.Type: ApplicationFiled: January 10, 2013Publication date: May 16, 2013Inventors: Valerie A. Kickhoefer, Leonard H. Rome, Kathleen A. Kelly, Cheryl I. Champion
-
Publication number: 20130121962Abstract: The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions.Type: ApplicationFiled: December 20, 2012Publication date: May 16, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Patent number: 8440206Abstract: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the prevention and/or treatment of tuberculosis are also disclosed.Type: GrantFiled: December 20, 2011Date of Patent: May 14, 2013Assignees: Oregon Health & Science University, The United States of America, as represented by the Department of Veteran AffairsInventors: David Lewinsohn, Deborah Lewinsohn
-
Patent number: 8431133Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.Type: GrantFiled: February 20, 2012Date of Patent: April 30, 2013Assignee: OmniGen Research, L.L.C.Inventors: Neil Elliott Forsberg, Steven Bruce Puntenney
-
Patent number: 8431136Abstract: An immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates is provided, wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of all the at least two further bacterial saccharide conjugates.Type: GrantFiled: June 23, 2006Date of Patent: April 30, 2013Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 8414899Abstract: The present invention provides improved vaccine compositions having enhanced immunogenicity and methods of using same. The compositions and methods include immunogenic conjugates containing peptide carriers derived from heat shock protein 60 (HSP60). The known synthetic peptide carrier, p458, provides significantly improved immunogenicity when provided as a multimeric conjugate comprising a plurality of peptide carrier units conjugated to each antigen. Cell vaccine compositions comprising antigen presenting cells loaded with multimeric p458 conjugates are also provided.Type: GrantFiled: April 11, 2007Date of Patent: April 9, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Hila Amir-Kroll, Noam Cohen, Gabriel Nussbaum
-
Publication number: 20130084306Abstract: Described are vaccines having one or more antigens cholesterol and CpG. Aspects of the invention relate to the use of the vaccines of the invention for the treatment and/or prevention of human and animal disorders.Type: ApplicationFiled: May 27, 2011Publication date: April 4, 2013Applicant: Coley Pharmaceutical Group Inc.Inventors: Heather Lynn Davis, Risini Weeratna, Paul J. Dominowski
-
Patent number: 8409584Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.Type: GrantFiled: May 5, 2010Date of Patent: April 2, 2013Assignee: New York UniversityInventors: Thomas M. Wisniewski, Fernando Goni
-
Publication number: 20130078273Abstract: Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.Type: ApplicationFiled: November 26, 2012Publication date: March 28, 2013Inventors: Valerie A. Kickhoefer, Leonard H. Rome, Kathleen A. Kelly, Cheryl I. Champion
-
Patent number: 8404247Abstract: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.Type: GrantFiled: June 23, 2011Date of Patent: March 26, 2013Assignees: The Salk Institute for Biological Studies, The Scripps Research InstituteInventors: John Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager
-
Publication number: 20130071428Abstract: The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.Type: ApplicationFiled: March 15, 2011Publication date: March 21, 2013Applicants: STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN, ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMCInventors: Ferdinand Antonius Ossendorp, Cornelis Joseph Maria Melief, Jan Wouter Drijfhout
-
Publication number: 20130072881Abstract: An immunogenic composition comprising a plurality of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F conjugated to a carrier protein, and further comprising at least one preservative, preferably 2-phenoxyethanol (2-PE). The preservative-containing immunogenic compositions of the invention confer resistance to one or more micro-organisms and are useful for producing multi-dose vaccine formulations having advantageous properties with respect to long term stability of the different antigenic determinants in the immunogenic composition of choice. Related compositions and methods for measuring the efficacy of one or more preservatives in a vaccine formulation are also provided.Type: ApplicationFiled: May 25, 2011Publication date: March 21, 2013Applicant: WYETH LLCInventors: Lakshmi Khandke, Abbas Rashidbaigi
-
Patent number: 8398988Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminum hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminum hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminum hydroxyphosphate adjuvant.Type: GrantFiled: February 23, 2012Date of Patent: March 19, 2013Assignee: Novartis AGInventors: Mario Contorni, Lorenzo Tarli
-
Patent number: 8398990Abstract: Anti-glucan antibodies have been found to be protective against systemic fungal infection with C. albicans, but the protective efficacy can be inhibited by blocking antibodies. The invention provides an immunogenic composition comprising a glucan and a pharmaceutically acceptable carrier, characterized in that, when administered to a mammalian recipient, the composition elicits protective anti-glucan antibodies but does not elicit antibodies which inhibit the protective efficacy of the anti-glucan antibodies. The glucan may be presented on the surface of a protease-treated microbial cell or may be presented as a protein-glucan conjugate. The glucan may be substituted by a glucan mimotope, a peptidomimetic of a glucan mimotope, or nucleic acid encoding a mimotope. Anti-glucan-antibodies show broad spectrum microbicidal activity. ?-glucans are preferred, particularly those containing one or more ?-1,6 linkages.Type: GrantFiled: August 11, 2010Date of Patent: March 19, 2013Inventors: Antonio Cassone, Luciano Polonelli
-
Publication number: 20130052204Abstract: Provided are an immunogenic composition comprising polyglycerol phosphate (PGP) and methods for using the composition for treating or preventing staphylococcal infections. The PGP may be conjugated to a T-cell dependent antigen. Also provided are methods for synthesizing PGP and methods for conjugating PGP to a T-cell dependent antigen.Type: ApplicationFiled: November 15, 2010Publication date: February 28, 2013Inventors: Clifford M. Snapper, Andrew Lees, James J. Mond, David Schwartz
-
Publication number: 20130034580Abstract: The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like.Type: ApplicationFiled: September 28, 2012Publication date: February 7, 2013Applicant: WYETH LLCInventor: Wyeth LLC
-
Publication number: 20130034579Abstract: This disclosure relates to adjuvants for use in immunogenic compositions comprising at least one antigen and an aluminum compound comprising hydroxyl groups that has been treated with phosphate, carboxylate, carbonate, sulfate diphosphonate or a mixture of two or more of these compounds and methods of using these compositions for preventing and treating diseases are also provided.Type: ApplicationFiled: December 20, 2010Publication date: February 7, 2013Inventors: Kevin Harper, Belma Ljutic, Scott Gallichan, Martina Ochs-Onolemhemhen, Garry Morefield, Fernando Ausar, Marie-Danielle Salha
-
Patent number: 8361477Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminum phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.Type: GrantFiled: August 29, 2011Date of Patent: January 29, 2013Assignee: Novartis Vaccines and Diagnostics GmbHInventor: Astrid Borkowski
-
Patent number: 8357496Abstract: Method for the diagnosis or the screening of an arbovirus infection and preferably a flaviviridae infection and more preferably a flavivirus infection, reagents useful in said method and their applications. Said method comprises: (i) contacting a sample from the subject or animal with a solid support sensitized with an Ig binding protein which is directed against a specific class of Ig molecules of the subject or animal species under consideration and (ii) incubating the immunocomplex formed in (i) with a detector molecule consisting of a hybrid protein comprising at least an arboviral ED3 domain and an alkaline phosphatase (PhoA), the detection of said immunocomplex being the sign of the presence of an arbovirus in said sample.Type: GrantFiled: June 13, 2008Date of Patent: January 22, 2013Assignees: Institut Pasteur, Centre National de La Recherche ScientifiqueInventors: Hugues Bedouelle, Elodie Brient-Litzler, Philippe Dussart, Philippe Despres, Laetitia Bremand
-
Publication number: 20130017203Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.Type: ApplicationFiled: June 19, 2012Publication date: January 17, 2013Applicant: NEW YORK UNIVERSITYInventors: Victor J. TORRES, Francis ALONZO, III
-
Publication number: 20130004535Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.Type: ApplicationFiled: September 4, 2012Publication date: January 3, 2013Inventor: Astrid BORKOWSKI
-
Publication number: 20130004536Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.Type: ApplicationFiled: September 4, 2012Publication date: January 3, 2013Inventor: Astrid BORKOWSKI
-
Patent number: 8337863Abstract: The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to D. discoideum proteinase 1, as well as novel subunits thereof, and methods of making and using the conjugates in vaccines to treat sepsis and other infectious complications.Type: GrantFiled: February 6, 2012Date of Patent: December 25, 2012Assignee: EndoBiologics, IncorporatedInventors: Gary L. Gustafson, Dan C. DeBorde
-
Publication number: 20120321660Abstract: Process for conjugation of bacterial saccharides including Streptococcus pneumoniae and Haemophilus influenzae saccharides by reductive amination are provided herein.Type: ApplicationFiled: March 7, 2011Publication date: December 20, 2012Inventors: Ralph Leon Biemans, Pierre Duvivier, Ollivier Francis Nicolas Gavard
-
Patent number: 8333980Abstract: The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.Type: GrantFiled: November 13, 2008Date of Patent: December 18, 2012Assignee: Dynavax Technologies CorporationInventors: Gary Van Nest, Stephen F. Tuck, Joseph Eiden, Jr.
-
Publication number: 20120315293Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.Type: ApplicationFiled: January 20, 2012Publication date: December 13, 2012Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
-
Patent number: 8329190Abstract: The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and/or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as an active ingredient and/or lactic acid bacteria producing it and/or its supernatant of culture, in the manufacture of a medicament, an oral or topical product for cosmetic, dermatological or ophtalmological applications, a food or petfood composition for modulating bacterial colonization, immune responses and decreasing the inflammatory processes associated with bacterially-mediated disease and infection in the gastrointestinal tract, bone, skin, eye, ear, lung and oral cavity. The invention also relates to lipoteichoic acid selected thereof.Type: GrantFiled: October 7, 2008Date of Patent: December 11, 2012Assignees: Societe des Produits Nestle S.A., Nestec S.A.Inventors: Karine Vidal, Anne Donnet-Hughes, Dominique-Anne Granato, Irene Corthesy-Theulaz
-
Publication number: 20120301502Abstract: The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F or 33F) conjugated to a carrier protein, preferably CRM197. The immunogenic composition, preferably formulated as a vaccine on an aluminum-based adjuvant, provides broad coverage against pneumococcal disease, particularly in infants and young children.Type: ApplicationFiled: February 3, 2011Publication date: November 29, 2012Inventors: Michael J. Caulfield, Patrick J. Ahl, Jeffrey T. Blue, Jayme L. Cannon
-
Publication number: 20120301500Abstract: The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to D. discoideum proteinase 1, as well as novel subunits thereof, and methods of making and using the conjugates in vaccines to treat sepsis and other infectious complications.Type: ApplicationFiled: February 6, 2012Publication date: November 29, 2012Applicant: EndoBiologics, IncorporatedInventors: Gary L. Gustafson, Dan C. DeBorde
-
Publication number: 20120301501Abstract: The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunisation against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunisation against a microorganism. The invention describes three pneumococcal proteins SlrA, IgA1 proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis.Type: ApplicationFiled: February 15, 2012Publication date: November 29, 2012Applicant: MUCOSIS B.V.Inventors: Cornelis Johannes Leenhouts, Ronald de Groot, Peter Wilhelmus Maria Hermans
-
Publication number: 20120301510Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising CD1d-restricted antigens and immunosuppressants that provide tolerogenic immune responses.Type: ApplicationFiled: April 27, 2012Publication date: November 29, 2012Applicant: Selecta Biosciences, Inc.Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado